Biotech | 05 November 2021
Novavax files emergency use listing with WHO for Covid-19 vaccine
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
Cortrophin gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders. It acquired the NDA for cortrophin gel from Merck & Co. in 2016
Expertise in exosomes isolation and characterization will drive innovation in this field
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Filing marks first protein-based vaccine submitted to MHRA for authorization
Support from DFC will help produce one billion vaccine doses by the end of 2022
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
This strategic collaboration will enable continued innovation in cancer care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
